Lumera Corporation, an emerging leader in the field of nanotechnology, announced today that Baylor Research Institute (BRI) had agreed to purchase its beta ProteomicProcessor Biosensor instrument.
"Dr. Jacques Banchereau's work at the Institute is cutting-edge research in the field of Immunology which focuses on cancer vaccines, autoimmune and infectious diseases, and organ transplantation," said Ron Dudek, Product Development Manager, Bioscience Business Unit. "We look forward to demonstrating the ProteomicProcessor's high-throughput measurement capability in Dr. Banchereau's multi-faceted program. Our label-free technology coupled with our NanoCapture high-density microarrays should lower the cost and increase the speed of data acquisition for the life sciences, drug discovery and translational medicine researchers."
Dr. Banchereau's team at Baylor Research Institute, a component of Baylor Health Care System in Dallas, plans to use the ProteomicProcessor to measure serum protein levels. "The strength of this instrument for us is the ability to look at many serum protein levels at the same time without having to label the proteins first," states Dr. Banchereau.
As previously announced, Lumera's strategy in this arena is to place five beta units with highly respected, world-renowned research organizations to demonstrate and establish new applications which take advantage of the instrument's unprecedented throughput. This is the third placement of the biosensor.
